Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 22, 2017
Pharmacy Choice - Pharmaceutical News - Lonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic Acidemia [Sport360] - October 22, 2017

Pharmacy News Article

 2/17/17 - Lonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic Acidemia [Sport360]

Global leader in viral gene and cell therapy manufacturing Lonza Houston and Selecta Biosciences, a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious diseases that avoid unwanted immunogenicity, have entered into a strategic manufacturing agreement.

Under the terms of the agreement, Lonza will produce an Anc80-AAV-based gene therapy product for Selecta`s proprietary programme for the treatment of Methylmalonic Acidemia (MMA), a rare inborn error of metabolism. The company may also produce other Anc80-based in the future.

This relationship will leverage Lonza`s expertise in the development of robust and industry-scale manufacturing platforms for viral-based products. Data shows that Anc80-AAV, an in silico-designed synthetic gene therapy vector, has the potential to provide superior gene expression levels in retina, liver, muscle, cochlea`s outer hair cells and other tissue targets in preclinical studies, as well as reduced cross-reactivity as compared to naturally occurring adeno-associated viral vectors (AAV) currently in clinical development.

Head of emerging technologies business unit for Lonza`s pharma&biotech segment Andreas Weiler, said: "This agreement with Selecta Biosciences continues to demonstrate Lonza`s leadership position in the cell and gene therapy space.

"Lonza will utilise our extensive current good manufacturing practice (cGMP) manufacturing knowledge and world-class quality systems to help Selecta Biosciences develop promising novel therapeutics for patients impacted by MMA and other devastating diseases.

"We at Selecta are focused on combining novel and proprietary viral vectors with our immune tolerance Synthetic Vaccine Particles (SVP) to enable the first non-immunogenic gene therapies, providing the potential for repeat dosing."

Selecta`s president, chief executive officer (CEO) and chairman Werner Cautreels said: "We view Lonza, one of the industry`s largest contract manufacturers of biologics and a leading supplier in gene therapy, as an ideal partner. They already have invested in developing various expression technologies and they share our excitement about Anc80.

"We look forward to working with them to bring the first Anc80-based program into the clinic as a potential treatment for patients afflicted with methylmalonic academia (MMA)."

(c) 2017 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Oct 23: Vitamin D Primer for Pharmacy Professionals
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement